Amgen 2010 Annual Report Download - page 114

Download and view the complete annual report

Please find page 114 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

Exhibit No. Description
10.22 Amendment No. 13 to the Shareholders’ Agreement, dated June 28, 2007 (with certain confidential
information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2007
on August 9, 2007 and incorporated herein by reference.)
10.23 Product License Agreement, dated September 30, 1985, and Technology License Agreement, dated
September 30, 1985, between Kirin-Amgen, Inc. and Ortho Pharmaceutical Corporation. (Filed as an
exhibit to Form 10-Q for the quarter ended June 30, 2000 on August 1, 2000 and incorporated herein by
reference.)
10.24 Research, Development Technology Disclosure and License Agreement: PPO, dated January 20, 1986,
by and between Kirin Brewery Co., Ltd. and Amgen Inc. (Filed as an exhibit to Amendment No. 1 to
Form S-1 Registration Statement on March 11, 1986 and incorporated herein by reference.)
10.25 Assignment and License Agreement, dated October 16, 1986 (effective July 1, 1986, between Amgen
and Kirin-Amgen, Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2000 on
March 7, 2001 and incorporated herein by reference.)
10.26 G-CSF United States License Agreement, dated June 1, 1987 (effective July 1, 1986), Amendment
No. 1, dated October 20, 1988, and Amendment No. 2, dated October 17, 1991 (effective November 13,
1990), between Kirin-Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K for the year ended
December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.27 G-CSF European License Agreement, dated December 30, 1986, between Kirin-Amgen and Amgen,
Amendment No. 1 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated June 1,
1987, Amendment No. 2 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated
March 15, 1998, Amendment No. 3 to Kirin-Amgen, Inc. / Amgen G-CSF European License
Agreement, dated October 20, 1988, and Amendment No. 4 to Kirin-Amgen, Inc. / Amgen G-CSF
European License Agreement, dated December 29, 1989, between Kirin-Amgen, Inc. and Amgen Inc.
(Filed as exhibits to Form 10-K for the year ended December 31, 2000 on March 7, 2001 and
incorporated herein by reference.)
10.28 Agreement Regarding Governance and Commercial Matters, dated December 16, 2001, by and among
American Home Products Corporation, American Cyanamid Company and Amgen Inc. (with certain
confidential information deleted therefrom). (Filed as an exhibit to Amendment No. 1 to Form S-4
Registration Statement on March 22, 2002 and incorporated herein by reference.)
10.29 Amended and Restated Promotion Agreement, dated as of December 16, 2001, by and among Immunex
Corporation, American Home Products Corporation and Amgen Inc. (with certain confidential
information deleted therefrom). (Filed as an exhibit to Amendment No. 1 to Form S-4 Registration
Statement on March 22, 2002 and incorporated herein by reference.)
10.30 Description of Amendment No. 1 to Amended and Restated Promotion Agreement, effective as of
July 8, 2003, among Wyeth, Amgen Inc. and Immunex Corporation (with certain confidential
information deleted therefrom). (Filed as an exhibit to Form 10-K for the year ended December 31,
2003 on March 11, 2004 and incorporated herein by reference.)
10.31 Description of Amendment No. 2 to Amended and Restated Promotion Agreement, effective as of
April 20, 2004, by and among Wyeth, Amgen Inc. and Immunex Corporation. (Filed as an exhibit to
Form S-4/A on June 29, 2004 and incorporated herein by reference.)
10.32 Amendment No. 3 to Amended and Restated Promotion Agreement, effective as of January 1, 2005, by
and among Wyeth, Amgen Inc. and Immunex Corporation (with certain confidential information
deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2005 on May 4,
2005 and incorporated herein by reference.)
98